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Abstract
Background: To examine the circulating microRNA (miRNA) expression profile in a mouse model of diet-induced
obesity (DIO) with subsequent weight reduction achieved via low-fat diet (LFD) feeding.
Results: Eighteen C57BL/6NCrl male mice were divided into three subgroups: (1) control, mice were fed a standard
AIN-76A (fat: 11.5 kcal %) diet for 12 weeks; (2) DIO, mice were fed a 58 kcal % high-fat diet (HFD) for 12 weeks; and
(3) DIO + LFD, mice were fed a HFD for 8 weeks to induce obesity and then switched to a 10.5 kcal % LFD for 4
weeks. A switch to LFD feeding led to decreases in body weight, adiposity, and blood glucose levels in DIO mice.
Microarray analysis of miRNA using The Mouse & Rat miRNA OneArray® v4 system revealed significant alterations in the
expression of miRNAs in DIO and DIO + LFD mice. Notably, 23 circulating miRNAs (mmu-miR-16, mmu-let-7i,
mmu-miR-26a, mmu-miR-17, mmu-miR-107, mmu-miR-195, mmu-miR-20a, mmu-miR-25, mmu-miR-15b, mmu-miR-15a,
mmu-let-7b, mmu-let-7a, mmu-let-7c, mmu-miR-103, mmu-let-7f, mmu-miR-106a, mmu-miR-106b, mmu-miR-93,
mmu-miR-23b, mmu-miR-21, mmu-miR-30b, mmu-miR-221, and mmu-miR-19b) were significantly downregulated in
DIO mice but upregulated in DIO + LFD mice. Target prediction and function annotation of associated genes revealed
that these genes were predominantly involved in metabolic, insulin signaling, and adipocytokine signaling pathways
that directly link the pathophysiological changes associated with obesity and weight reduction.
Conclusions: These results imply that obesity-related reductions in the expression of circulating miRNAs could be
reversed through changes in metabolism associated with weight reduction achieved through LFD feeding.
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Background
Obesity is associated with insulin resistance and an ab-
normal inflammatory response [1], and the strong asso-
ciations suggest that adipose tissue plays a prominent
role in the onset and progression of these comorbidities
[2]. White adipose tissue (WAT) has been characterized
as an endocrine organ [3], as it produces endocrine-
acting peptides such as leptin, and it is metabolically
important, with excess levels being associated with
metabolic syndrome [4, 5]. High fat uptake leads to
metabolic alterations in adipose tissue that increase the
levels of circulating free fatty acids in the blood [6].
This leads to macrophage activation and the production
of proinflammatory cytokines via Toll-like receptors,
resulting in inflammation in adipose tissue [6]. When
allowed ad libitum access to a high-fat diet (HFD),
C57BL/6J mice develop insulin resistance and obesity
in a manner that resembles disease progression in humans
[7]. Increased energy expenditure and decreased energy
intake are the two most commonly recommended lifestyle
changes to reduce adiposity and restore insulin sensitivity
in the treatment of diet-induced obesity (DIO) and associ-
ated comorbidities [8]. Calorie restriction is effective in
improving insulin sensitivity and decreasing both body
weight and percent body fat [9]. In addition, reductions in
* Correspondence: m93chinghua@gmail.com
†Equal contributors
1Department of Plastic and Reconstructive Surgery, Kaohsiung Chang Gung
Memorial Hospital and Chang Gung University College of Medicine, No. 123,
Ta-Pei Road, Niao-Song District, Kaohsiung City 833, Taiwan
Full list of author information is available at the end of the article
© 2015 Hsieh et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hsieh et al. BMC Genomics  (2015) 16:699 
DOI 10.1186/s12864-015-1896-3
body weight and improvements in insulin sensitivity can
also be achieved by reducing the percentage fat in a diet,
i.e., by switching from a HFD to a low-fat diet (LFD) [10].
MicroRNAs (miRNAs) are endogenous small RNAs
that post-transcriptionally regulate gene expression,
and they have been demonstrated to have important
roles in numerous disease processes. There is growing
evidence that miRNAs play an important role in regu-
lating adipose tissue pathways that control a range of
processes, including adipogenesis, insulin resistance,
and inflammation [11–13]. Many miRNAs are dysregu-
lated in the metabolic tissues of obese animals and
humans, potentially contributing to the pathogenesis of
obesity-associated complications [11–13]. In addition,
recent studies identified several miRNAs expressed in
metabolic organs that could be used as feasible thera-
peutic targets for obesity and its consequent patholo-
gies [11, 13]. Recently, circulating serum miRNAs were
found to display specific expression patterns, suggesting
that miRNA profiles may represent fingerprints for
various diseases [14, 15]. In addition, despite the ubi-
quitous presence of ribonucleases, serum miRNAs
levels are remarkably stable and reproducible [16, 17],
and they function in cell-to-cell communication [18].
Currently, how changes in miRNA profiles might affect
adipose tissue at the functional and molecular level and to
what extent they differ in response to weight-reduction
strategies are not well understood. This information is im-
portant in the development of dietary anti-obesity in-
terventions [19]. As circulating miRNAs potentially
play an important role in regulating the pathophysi-
ology of obesity and they are potential therapeutic tar-
gets, we hypothesized the weight reduction may change
the circulating miRNAs expression. Our study aim was
to profile the expression of circulating miRNAs in a
mouse model of DIO with subsequent weight reduction
achieved through LFD feeding.
Methods
Ethics statement
This study was conducted in strict accordance with
guidelines on the use of laboratory animals, and every
effort was made to minimize the suffering of affected an-
imals. Animal protocols were approved by the IACUC of
Chang Gung Memorial Hospital, Taiwan (permission
number No. 2012091002).
Animal experiments
C57BL/6NCrl mice were purchased from BioLasco (Taipei,
Taiwan). Animals were housed, and surgical procedures, in-
cluding analgesia, were performed in an Association for
Assessment and Accreditation of Laboratory Animal Care
International-accredited SPF facility according to national
and institutional guidelines. In this experiment, 18 male,
wild-type C57BL/6NCrl mice were randomly assigned to
three subgroups (n = 6 in each group) as follows: (1)
control, mice were fed a standard AIN-76A (fat: 11.5
kcal %) diet ad libitum for 12 weeks; (2) DIO, mice
were fed a 58 kcal % HFD (D12331; Research Diets
Inc., New Brunswick, NJ) ad libitum for 12 weeks to
induce obesity; and (3) DIO + LFD, mice were fed a
58 kcal% HFD (D12331) ad libitum for 8 weeks to
induce obesity and then fed a 10.5 kcal% LFD (D
12329; Research Diets Inc.) for 4 weeks. Weight mea-
surements were performed weekly, and a glucose tol-
erance test was performed at the beginning and end
of the experiment to confirm that HFD-fed mice de-
veloped an obese and glucose intolerance phenotype.
Briefly, mice were fasted for 5 h, and baseline blood
glucose levels were measured with an Accu-Check
Advantage blood glucose meter (Roche, New Jersey,
USA) using blood collected from the tail vein. Mice
(n = 6 in each group) were injected intraperitoneally
with 2 g of glucose per kilogram body weight in
sterile PBS. The glucose level was measured via tail
vein blood (~10 μL) at t = -30 and 0 (pre) and t = 15,
30, 60, 90, and 120 min after the glucose infusion.
Data were averaged and graphed as blood glucose
level as a function of time. To reflect the circulating
levels of glucose during the glucose tolerance test
(GTT), we calculated the total area under the curve
(AUC) of the glucose concentration versus time by
the linear trapezoidal rule for the period of 0 - 120
min after glucose infusion. To avoid the effect of loss
of blood in GTT experiment or uncertain effect or
repeat tail punctures on subsequent miRNAs expres-
sion and cytokine assay, additional groups of mice
under the same model were used for further experi-
ments. After the end of the experiment, all mice were
euthanized, and the abdominal mesenteric WAT of
each mouse was removed and weighed. The adipose
tissue block embedded in paraffin was sectioned at 5 μm
to measure the adipocyte area. Three 5 μm-thickness sec-
tions of the same fat specimen at 50 μm distance was
mounted on glass plate and stained with hematoxylin and
eosin. Two different microscopic fields (magnifica-
tion × 100) per plate were photographed and 100 adi-
pose cells were arbitrarily selected in the center of
field and their cell diameters were assessed by tracing
the outline of each adipocyte. The mean adipocyte
area was measured from the WAT of control and ex-
perimental mice (n = 4 in each group) using Image-Pro
Plus image analysis software (Carl Zeiss, Oberkochen,
Germany) and expressed in terms of square micrometers.
The cells were randomly chosen, and the person analyzing
the images was blinded to the group assignments. At the
indicated time of the experiment, 1 mL of whole blood
was collected via cardiac puncture into a plain tube and
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allowed to clot for 1 h. Samples were centrifuged at
3000 × g for 10 min, and sera were aliquoted and stored
at −80°C until further analysis.
Cytokine assays
Serum cytokine concentrations were analyzed using
two complementary Bio-Plex suspension arrays (M60-
00003J7 and M60-00007NY) covering all cytokine bio-
markers potentially involved in inflammation (n = 6 in
each group). Eleven biomarkers (IL-1β, IL-2, IL-4, IL-
5, IL-6, IL-10, IL-12(p70), IL-17, GM-CSF, IFN-γ, and
TNF-α) were assessed simultaneously using the Bio-
Plex system (BioRad, Hercules, CA). Assays were
performed on four biological replicates per the manufac-
turer’s instructions. Results are expressed in picograms
per milliliter of serum.
RNA isolation and preparation
Total RNA was extracted from serum using the mir-
Vana™ miRNA Isolation Kit (Life Technologies, NY).
Purified RNA was quantitatively evaluated by measuring
its absorbance at 260 nm using an SSP-3000 Nanodrop
spectrophotometer (Infinigen Biotechnology, Inc., City
of Industry, CA), and RNA quality was assessed using a
Bioanalyzer 2100 (Agilent Technologies, Santa Clara,
CA). Total RNA (10 ng) was reverse-transcribed into
cDNA using a TaqMan miRNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA). Target miR-
NAs were reverse-transcribed using sequence-specific
stem-loop primers, and cDNA was used for quantitative
real-time polymerase chain reaction (qPCR).
miRNA microarray analysis
The Mouse & Rat miRNA OneArray® v4 (Phalanx
Biotech Group, Hsinchu, Taiwan) array used in this
experiment contains 144 experimental control probes,
1157 unique mouse miRNA probes, and 680 rat
miRNA probes, based on the miRBase 18 database.
Three biological replicates of each group of mice
were used in miRNA microarray experiments. Mouse
genome-wide miRNA microarray experimental and
statistical analyses were performed by Phalanx Biotech
Group. Briefly, fluorescent targets were prepared from
2.5 μg of total RNA using the miRNA ULS™ Labeling
Kit (Kreatech Diagnostics, Amsterdam, Netherlands).
Labeled miRNA targets enriched using NanoSep 100K
(Pall Corporation, Port Washington, NY) were hybridized
to The Mouse & Rat miRNA OneArray® v4 in Phalanx
hybridization buffer in the OneArray® Hybridization
Chamber. After overnight hybridization at 37 °C,
non-specifically bound targets were removed by three
washing steps (Wash I, 37 °C, 5 min; Wash II, 37 °C,
5 min and 25 °C, 5 min; and Wash III, rinse 20 times).
Slides were dried by centrifugation and scanned using an
Axon 4000B scanner (Molecular Devices, Sunnyvale,
CA). The signal intensities of Cy5 fluorescence in each spot
were analyzed using GenePix 4.1 software (Molecular
Devices, Sunnyvale, CA) and processed using R language
(http://www.r-project.org/) with two packages: limma
(http://www.bioconductor.org/packages/release/bioc/html/
limma.html) and genefilter (http://www.bioconductor.org/
packages/release/bioc/html/genefilter.html). Spots with
flag < 0 were filtered out, and the remaining spots were log
2 transformed and normalized using the 75 % media scaling
normalization method. Normalized spot intensities were
converted into gene expression ratios between the control
and treatment groups. Spots with expression ratios ≤0.5
or ≥2, as well as with p < 0.05, were selected for further
analysis. Differentially expressed miRNAs were subjected
to hierarchical cluster analysis using average linkage
and Pearson’s correlation as the measure of similarity.
The miRNA array data have been deposited in the
NCBI Gene Expression Omnibus with the accession
number GSE61005. Five miRNAs detected by array
analysis were selected and quantified by qPCR using
the Applied Biosystems 7500 Real-Time PCR System (Life
Technologies) to confirm the upregulation of miRNA ex-
pression in the DIO+ LFD group. Twenty-five femtomoles
of single-stranded cel-miR-39 synthesized by Invitrogen
(Carlsbad, CA) was spiked into 400 μL of serum as an in-
ternal control for the expression of each miRNA.
Target prediction, GO enrichment, and KEGG pathway
analyses
Target prediction was performed to identify the target
genes of the identified dysregulated miRNAs by inte-
grating all three public databases (TargetScan, PicTar,
and miRanda). This method firstly mapped all target
gene candidates to GO terms in the database (http://
www.geneontology.org/), calculated gene numbers for
each term, and then used a hypergeometric test to find
significantly enriched GO terms in target gene candidates
compared to the reference gene background. Bonferroni’s
correction for the p-value was used to obtain a corrected
p-value. GO terms with corrected p-values ≤ 0.05 were de-
fined as significantly enriched in target gene candidates.
To reveal the main pathways in which the target gene can-
didates are involved, pathway analysis using a major public
pathway-related database, KEGG, was performed to iden-
tify significantly enriched metabolic pathways or signal
transduction pathways in target gene candidates com-
pared with the whole reference gene background. Genes
with FDR ≤ 0.05 were considered significantly enriched
among the target gene candidates.
Statistical analysis
The body weight of mice are expressed as the mean with
a confidence interval. All other experimental data are
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expressed as the mean ± standard error of the mean.
Analysis of variance combined with a Bonferroni post
hoc correction was performed to identify significant dif-
ferences in body weight, weight of fat, adipocyte area,
glucose levels, and serum cytokine levels. A p value of
0.05 was regarded as the level of statistical significance.
Results
LFD decreased body weight and adiposity
In comparison with the C57BL/6NCrl mice fed the stand-
ard diet, feeding with the HFD significantly increased body
weight (Fig. 1). By contrast, after the change from HFD
feeding to LFD feeding, the body weight of DIO mice
decreased quickly, with the mean body weight stabilizing
after 4 weeks on the LFD. Abdominal mesenteric WAT
was also significantly larger in the DIO mice than in con-
trol mice, and the mice that were switched to the LFD had
significantly less abdominal mesenteric WAT than those
that remained on the HFD (Fig. 2a). However, the lower
amount of abdominal mesenteric WAT was not accom-
panied by a significantly smaller adipocyte area (Figs. 2b
and 3). Notably, because the fat specimen chosen at 50
μm distance was less than the mean diameter of the adi-
pocytes, there may be exist a selection bias that some
measured adipocytes were repeatedly calculated. However,
we expect this selection bias is not significant because the
tissue section was chosen in a fixed distance and the
counting of high number of adipocytes could decrease the
deviation of calculated mean adipocyte area. After injec-
tion of glucose to the control mice, blood glucose levels
increased to a peak of 350 mg/dL after 15 min, and then
gradually returned to baseline after 120 min. In the DIO
mice, blood glucose concentrations at 30 to 120 min dur-
ing the GTT were significantly higher than those in the
control mice (Fig. 4a). HFD-fed animals displayed signifi-
cant impairment in glucose tolerance, as evidenced by a
90 % higher incremental glucose AUC (Fig. 4b). In
addition, significantly lower glucose level was observed at
30 min after glucose injection for the LFD-fed mice rela-
tive to the HFD-fed mice (Fig. 4a), resulting in an around
15 % lower glucose AUC (Fig. 4b).
LFD did not induce the differential expression of
inflammatory cytokines
Of the 11 biomarkers measured (IL-1β, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12 (p70), IL-17, GM-CSF, IFN-γ, and
Fig. 1 The body weight of C57BL/6NCrl mice on a weekly basis till
12 weeks (n = 6 in each group). Control: the mice fed with the
standard diet; DIO: the mice fed with high-fat diet; DIO + LFD: the
mice fed with high-fat diet for 8 weeks to induce obesity, then
change to low-fat diet for subsequent 4 weeks. *(red color), P < 0.05
vs. control. *(green color), P < 0.05 vs. DIO. The body weight of mice
are expressed as the mean a ± 80 % confidence interval
Fig. 2 a The weight of abdominal mesenteric white adipose tissue and b the adipocyte area of C57BL/6NCrl mice in groups of control, DIO, DIO
+ LFD at 12w. **,P < 0.01 vs. control. ††, P < 0.01 vs. DIO (n = 4 in each group)
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TNF-α), IL-1β had the highest expression in serum,
followed by TNF-α, IL-10, and IL-12 (p70) (Fig. 5).
However, there were no significant differences in expres-
sion among the groups.
Upregulated miRNA targets in microarray analysis
Greater than 2-fold differences in serum miRNA expres-
sion between DIO mice and controls as well as between
DIO + LFD and DIO mice (p < 0.05) were identified for
further analysis. The microarray and qPCR results were
in agreement, with a Pearson correlation value of 0.891
(Additional file 1), under the limitation of only five miR-
NAs being selected for analysis. Unsupervised hierarch-
ical clustering of all differentially expressed serum
miRNAs was conducted to separate samples from ex-
perimental or control subjects into different groups
(Fig. 6). In microarray experiments of DIO mouse sera,
eight miRNAs were upregulated, and 34 were down-
regulated (Table 1). In addition, in the sera of DIO +
LFD mice, 28 miRNAs were upregulated, and 10 were
downregulated (Table 2). As shown in the Venn dia-
gram in Fig. 7, notably, 23 of the 28 upregulated miR-
NAs in DIO + LFD mice (mmu-miR-16, mmu-let-7i,
mmu-miR-26a, mmu-miR-17, mmu-miR-107, mmu-miR-
195, mmu-miR-20a, mmu-miR-25, mmu-miR-15b, mmu-
miR-15a, mmu-let-7b, mmu-let-7a, mmu-let-7c, mmu-
miR-103, mmu-let-7f, mmu-miR-106a, mmu-miR-106b,
mmu-miR-93, mmu-miR-23b, mmu-miR-21, mmu-miR-
30b, mmu-miR-221, and mmu-miR-19b) were downregu-
lated in the DIO mice. Only five miRNAs (mmu-miR-
451, mmu-miR-223, mmu-miR-92a, mmu-miR-200c,
and mmu-miR-873) were differentially expressed, im-
plying that the majority of miRNA downregulation as-
sociated with obesity could be reversed by LFD treatment.
By contrast, of the eight upregulated miRNAs in DIO
mice, only one (mmu-miR-711) was significantly down-
regulated in DIO + LFD mice.
Target prediction and function annotation
To further understand the physiological functions and
biological processes associated with the 23 miRNAs,
target prediction was performed by integrating three
public databases (TargetScan, PicTar, and miRanda),
and 1082 target genes were identified. GO annotation
and KEGG pathway analysis was also performed to
identify functional modules regulated by these 23 miR-
NAs. In GO annotation analysis, cellular processes,
biological regulation, metabolic processes, primary
Fig. 3 Hematoxylin and eosin stain of the paraffin-embedded white adipose tissue at 5 μm section of C57BL/6NCrl mice in groups of control,
DIO, DIO + LFD at 12w
Fig. 4 Blood glucose concentrations (a) and area under the curve (AUC) quantification (b) during a 120-min glucose tolerance test in groups of
control, DIO, DIO + LFD at 12w. *(red color), P < 0.05 vs. control. *(green color), P < 0.05 vs. DIO
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metabolic processes, and cellular metabolic processes
were the most significantly enriched GO terms (Fig. 8).
KEGG pathway analysis revealed 142 pathways associ-
ated with these miRNA targets. Among these, meta-
bolic pathways were the most enriched, with 1024
associated genes, followed by MAPK signaling, actin
cytoskeleton regulation, secondary metabolite biosyn-
thesis, focal adhesion, insulin signaling, calcium sig-
naling, cytokine-cytokine receptor interaction, tight
junctions, phagosomes, and adipocytokine signaling
pathways (Table 3). These results suggest that these
targets have a high possibility of being regulated by
miRNAs during obesity and weight reduction through
LFD feeding; however, the possibility of false-positive
results from the prediction algorithm always exists.
Discussion
Switching to a LFD is an effective intervention to pro-
mote weight loss and improve metabolic health parame-
ters in obesity [19]. Although morbid obesity is
considered a systemic inflammatory state, the serum in-
flammatory profile of C57BL/6 mice, as measured by an
antibody array, revealed that DIO mice had higher lep-
tin, IL-6, and LPS-induced chemokine concentrations
and lower concentrations of all other chemokines/cyto-
kines than control mice [20]. In this study, we demon-
strated that LFD feeding reduced the body weight and
adiposity of DIO mice; however, there was no significant
difference in the expression of the 11 measured cyto-
kines between DIO and DIO + LFD mice, suggesting that
DIO mice may be in an early state of obesity. By con-
trast, significantly dysregulated miRNAs were identified
in both groups. Notably, most (23 of 28) of these circu-
lating miRNAs were upregulated in DIO + LFD and
downregulated in DIO mice, implying that the downreg-
ulation of these miRNAs by obesity could be reversed by
LFD treatment. In addition, target prediction and func-
tion annotation revealed that the target genes associated
with these 23 differentially expressed miRNAs are
involved in metabolic, insulin, and adipocytokine signal-
ing pathways that directly link the pathophysiological
changes that occur during obesity and weight reduction.
Therefore, whether miRNA supplementation represents
a potential therapeutic strategy to treat obesity is an in-
teresting topic requiring further robust investigations to
clarify.
As many miRNAs are extensive regulators of adipo-
cyte development and function, their differential ex-
pression in the adipose tissue of mice in response to
HFD-induced obesity has been explored and discussed
in a number of articles [11–13, 21]. For example, in a
microarray experiment, 26 miRNAs were upregulated in
WAT in response to HFD feeding, including mmu-miR-
342-3p, mmu-miR-222, mmu-miR-221, mmu-miR-142-
3p, mmu-miR-142-5p, mmu-miR-21, mmu-miR-335-5p,
mmu-miR-146a, mmumiR-146b, mmu-miR-647*, and
mmu-miR-379, whereas the following miRNAs were
downregulated: mmu-miR-141, mmu-miR-200a, mmu-
miR-200b, mmumiR-200c, mmu-miR-122, mmu-miR-
204, mmu-miR-133b, mmu-miR-1, mmu-miR-30a*,
mmu-miR-130a, mmu-miR-192, mmu-miR-193a-3p,
mmu-miR-203, mmu-miR-378, and mmumiR-30e*
[21]. Some of the circulating miRNAs identified in this
study have also been reported in the adipose tissue of
DIO mice or implicated in adipogenic processes [11–
13], including Let-7, miR-103, miR-15, the miR-17-92
cluster (miR-17, miR-20a, and miR-92a), miR-21, miR-
221, and miR-30b. However, these miRNA that were
previously reported to be upregulated in adipose tissue
were downregulated in DIO mice but upregulated in
DIO + LFD mice in this study, casting doubt on the
suggestion that these circulating miRNAs originated
Fig. 5 Concentrations of serum cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12(p70), IL-17, GM-CSF, IFN-γ, TNF-α) analyzed by the Bio-Plex
Multiplex cytokine assay at 12w in the mice in groups of control, DIO, DIO + LFD (n = 6 in each group)
Hsieh et al. BMC Genomics  (2015) 16:699 Page 6 of 11
from the adipose tissue of obese mice. Notably, al-
though the origin of circulating miRNAs is debatable,
the expression profile of circulating miRNAs is obvi-
ously different from those in pathological tissues [22–
24]. Whether these circulating miRNAs originated from
adipose tissue, blood cells, or other cells of the circulat-
ing system requires further experimentation to clarify.
In this study, some of the identified dysregulated miR-
NAs have been linked to obesity or adipogenesis in the
literature. Among them, five members of the Let-7 fam-
ily (mmu-let-7a, mmu-let-7b, mmu-let-7c, mmu-let-7f,
and mmu-let-7i) were dysregulated in response to obes-
ity and weight reduction following LFD feeding. Mice
with global overexpression of Let-7 are viable, but they
have reduced body size and weight [25]. In mice, 12
genes encode members of the Let-7 family, which in-
cludes nine slightly different miRNAs (Let-7a, Let-c, and
Let-7f [all encoded by two genes], and Let-7b, Let-7d,
Fig. 6 Hierarchical cluster analysis of differentially expressed circulating
miRNAs in the serum of C567BL/6 mice in groups of control, DIO,
DIO + LFD (n = 3 in each group)
Table 1 miRNA targets dys-regulated more than 2-fold in serum
of C57BL/6NCrl mice at 12w high-fat diet-induced obesity vs.







mmu-miR-711 2.15 0.00 mmu-let-7i −3.98 0.01
mmu-miR-712 1.58 0.04 mmu-miR-16 −3.83 0.01
mmu-miR-713 1.41 0.03 mmu-miR-15a −3.02 0.01
mmu-miR-714 1.12 0.05 mmu-miR-26a −2.61 0.00
mmu-miR-715 1.07 0.01 mmu-miR-107 −2.53 0.00
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mmu-miR-717 1.05 0.05 mmu-miR-17 −2.49 0.00
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Let-7e, Let-7g, Let-7i, and miR-98 [all encoded by one
gene]). All Let-7 family members are believed to have
similar functions because they share a common seed re-
gion (nucleotides 2–8), which mediates interactions be-
tween miRNA and target mRNAs [25]. Furthermore,
Let-7 transgenic mice exhibit impaired glucose tolerance
because of diminished glucose-induced insulin secretion,
and anti-miR–induced silencing of Let-7 has been
proven to improve blood glucose levels and insulin re-
sistance in obese mice [25].
In vivo, miR-103 is downregulated in the mature adi-
pocytes of obese mice [26] and upregulated during the dif-
ferentiation of human and murine pre-adipocytes [27, 28].
A 9-fold upregulation of miR-103 was noted during
early adipogenesis in 3T3-L1 pre-adipocyte cells, and
lipid droplet formation was accelerated when it was ec-
topically expressed [26]. miR-103 is also upregulated
during porcine adipogenesis, and its inhibition sup-
presses adipogenesis [26].
miR-15a overexpression leads to a decrease in the
number, but an increase in the size, of murine adipo-
cytes by inhibiting Delta-like 1 homolog expression [29].
In a study of miRNA libraries reconstructed from pre-
and post-differentiated 3T3-L1 cells, it was noted that
miR-15a may not be related to the actual differentiation
process, but it may induce growth arrest and/or hormo-
nal stimulation [30]. In addition, the miR-17-19 cluster,
which comprises seven miRNAs (miR-17-5p, miR-17-3p,
miR-18, miR-19a, miR-20, miR-19b, and miR-92-1) and
promotes cell proliferation in various cancers, has been
demonstrated to be significantly upregulated at the
clonal expansion stage of adipocyte differentiation. MiR-
17-92 has been revealed to target Rb2/p130, an import-
ant early regulator of pre-adipocyte clonal expansion
[31], and the stable transfection of 3T3L1 cells with
miR-17-92 resulted in accelerated differentiation and in-
creased triglyceride accumulation after hormonal stimu-
lation [32]. The adipogenic miR-21 has also been
demonstrated to be upregulated in human obesity [33]
and to enhance adipogenesis in human adipose tissue-
derived mesenchymal stem cells (hASCs) by mediating
TGF-β signaling [34].
The miR-30 family has been found to be important for
adipogenesis [12]. In this study, miR-30a, miR-30b, and
miR-30c were significantly downregulated in obese mice,
and miR-30b was significantly upregulated after LFD
feeding. MiR-30 family members are strongly upregu-
lated during adipogenesis in human cells, and inhibition
of miR-30 inhibits adipogenesis [12]. miR-30 family
members have also been demonstrated to act as positive
regulators of adipocyte differentiation in a human adi-
pose tissue-derived stem cell model [35]. Overexpression
of miR-30a and miR-30d stimulates adipogenesis, and it
has been demonstrated that miR-30a and miR-30d target
RUNX2, a major regulator of osteogenesis and a potent
inhibitor of PPARγ, the master gene in adipogenesis
[36]. MiR-30c has been found to be upregulated in adi-
pogenesis and to enhance adipogenesis in hASCs, and it
appears to target two genes (PAI-1 and ALK2) in distinct
pathways [37]. Moreover, miR-30d has been identified as
a positive regulator of insulin transcription [38].
Furthermore, in this study, eight miRNAs (mmu-miR-711,
mmu-miR-712, mmu-miR-713, mmu-miR-714, mmu-miR-
715, mmu-miR-716, mmu-miR-717, and mmu-miR-574)
were upregulated in DIO mice. Of these, miR-712 is
a mechanosensitive miRNA that is upregulated in
endothelial cells by disturbed flow, which regulates
Table 2 miRNA targets dys-regulated more than 2-fold in
serum of C57BL/6NCrl mice following 4 w low-fat diet after 8
w high-fat diet-induced obesity vs. 12 w high-fat diet-induced
obesity (P-value < 0.05)
Up-regulated Down-regulated
DIO + LFD Fold
(log2)
p-value DIO + LFD Fold
(log2)
p-value
mmu-miR-16 3.48 0.00 mmu-miR-1983 −3.29 0.05
mmu-let-7i 3.23 0.01 mmu-miR-5112 −2.39 0.02
mmu-miR-26a 2.57 0.02 mmu-miR-1894 −2.18 0.02
mmu-miR-17 2.38 0.02 mmu-miR-5109 −1.88 0.01
mmu-miR-107 2.35 0.02 mmu-miR-711 −1.80 0.00
mmu-miR-451 2.34 0.00 mmu-miR-351* −1.37 0.04
mmu-miR-195 2.28 0.01 mmu-miR-700 −1.19 0.01
mmu-miR-20a 2.06 0.01 mmu-miR-1940 −1.15 0.03
mmu-miR-25 1.88 0.03 mmu-miR-204* −1.14 0.02
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endothelial dysfunction and atherosclerosis [39, 40].
MiR-717, which was first reported in mice, is encoded
by intron 3 of the body mass-associated glypican-3
(Gpc3) gene, and it plays an important regulatory role
in renal osmoregulation. Meanwhile, Gpc3 knockout
mice display increased body mass, renal dysplasia,
and perinatal mortality [41]. Bioinformatics analysis
enables functional annotation of MiR-717 orthologs to
determine the effect of its target genes on fat-related
traits [42]. However, the effects and mechanisms of
these eight upregulated miRNAs in the obese mice in
this study are poorly understood.
Conclusion
This study identified the expression profile of circulat-
ing miRNAs in a mouse model of DIO and DIO with
Fig. 7 Venn diagram of the changed miRNAs in the serum of C567BL/6 mice in groups of DIO and DIO + LFD
Fig. 8 Partial gene ontology (GO) classification annotated for the predicted target genes of 23 interesting up-regulated miRNAs. The figure shows
partial GO enrichment for the predicted target genes in cellular component, molecular function, and biological process. All the P < 0.001
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subsequent weight reduction through LFD feeding. The
results demonstrated that the majority of miRNA down-
regulation in association with obesity could be reversed by
LFD feeding. Target prediction and function annotation
revealed that the target genes associated with these 23 dif-
ferentially expressed miRNAs are involved in metabolic,
insulin, and adipocytokine signaling pathways that directly
link the pathophysiological changes that occur during
obesity and weight reduction.
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